galcanezumab (Emgality)

^[1]^[2]^[3]

Indications

monthly injection^[1]
loading dose of 240 mg loading dose (administered as two consecutive injections of 120 mg each), followed by monthly doses of 120 mg^[2]

injection site reactions (most common)
serious & prolonged hypersensitivity reactions can occur days after injection^[2]

↑ ^1.0 ^1.1 ^1.2 Orciari Herman A, Sadoughi S, Sofair A FDA Approves New Migraine Drug Physician's First Watch, Oct 1, 2018 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
Lilly's Emgality <TM> (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults. News Release. Sept 27, 2018 https://investor.lilly.com/news-releases/news-release-details/lillys-emgalitytm-galcanezumab-gnlm-receives-us-fda-approval
↑ ^2.0 ^2.1 ^2.2 ^2.3 ^2.4 FDA News Release. June 4, 2019 FDA approves first treatment for episodic cluster headache that reduces the frequency of attacks. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-episodic-cluster-headache-reduces-frequency-attacks
↑ HIGHLIGHTS OF PRESCRIBING INFORMATION EMGALITY (galcanezumab-gnlm) injection, for subcutaneous use http://pi.lilly.com/us/emgality-uspi.pdf